ImmunityBio Highlights Innovations at Jefferies London Healthcare Conference

$IBRX

ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology innovator, has announced its participation in the upcoming Jefferies London Healthcare Conference, scheduled for November 19-21 at the Waldorf Hilton in London. The event will include a fireside chat on November 19 at 2:30 PM GMT, where ImmunityBio’s leadership will discuss recent developments in immunotherapy and cell therapy, as well as the company’s broader strategic initiatives.

Headquartered in Culver City, California, ImmunityBio is focused on advancing therapies and vaccines designed to bolster the body’s natural immune defenses against cancers and infectious diseases. The company’s therapeutic platform includes a range of immunotherapy and cell-based treatments aimed at sustaining immune response. Among its key innovations is ANKTIVA®, an FDA-approved therapy for non-muscle invasive bladder cancer (CIS), which leverages the activation of natural killer cells, T cells, and memory T cells to deliver a lasting immune response.

ImmunityBio’s ongoing work extends beyond bladder cancer, with developments aimed at cancer vaccines and potential treatments that could reduce reliance on traditional high-dose chemotherapy. These innovations underscore a shift toward more effective, accessible, and streamlined treatment options within oncology and infectious disease care. However, the company faces several challenges, including regulatory requirements and the need for sustained funding to support ongoing clinical trials and product pipeline expansion.

Critical factors for ImmunityBio’s future success will include navigating the regulatory submission and review process, as well as scaling up manufacturing and commercial supply capabilities. The outcomes of current and future clinical trials, alongside the company’s ability to meet regulatory and operational demands, will be pivotal in determining its impact on the evolving landscape of cancer and infectious disease treatment.

**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**